Diabetes case study

Diabetes Case Study: Clinical Discovery and Therapy Adjustment in a Healthcare Worker

55-year-old female working as a registered nurse for 33 years.  Lives with her husband.  She has two adult children and grandchildren who live in Wisconsin.

  • Past Medical History: Uncontrolled type 2 diabetes (Diagnosed 2001, A1c 14.0% in October 2024), stroke X3 with hospitalization (most recent October 2024), high blood pressure (138/92), high cholesterol, peripheral neuropathy, diabetic retinopathy (vision loss), broken shoulder and left upper arm due to a fall in the past year, back pain
  • Social History: Tobacco use ¼ ppd since college- quit in 2022, high stress level
  • Status at Enrollment:
    • Resistant to engagement due to healthcare background
    • Experiencing both highs and lows with blood glucose – not taking insulin therapy as prescribed
    • Non-adherent to medication (insulin) due to dislike of needles and fear of lows
    • Unfortunately, non-adherence with insulin therapy led to highly uncontrolled diabetes and resulted in her stroke in October 2024.
  • Medications:
    • Diabetes: Novolin R Flexpen (short-acting insulin), Insulin Glargine (long-acting insulin), Dexcom (continuous blood glucose monitoring)
    • Post-Stroke Protocol: Clopidogrel, Aspirin
    • High Blood Pressure: Losartan, Carvedilol, Amlodipine
    • High Cholesterol: Atorvastatin
  • Interventions:
    • Pharmacist uncovered insulin non-adherence contributing to consistent episodes of highs and lows throughout the week
      • Worked with the provider to adjust the insulin regimen reduced Novolin R from 40 units three times daily with meals to 15 units three times daily with meals and 5 units at bedtime
    • Health Coach engaged and worked on stress reduction strategies, portion control with each meal, and enhanced opportunities for physical activity throughout the day.
  • Outcomes:
    • Adjusting the insulin regimen led to greater tolerability and adherence and resulted in her hemoglobin A1c dropping from 14% in October 2024 to 6.9% in June 2025.
  • Impact:
    • Patient enrolled in the program with highly unstable type 2 diabetes that has already resulted in multiple strokes, associated hospitalizations, and long-term deficits along with other secondary complications, including vision loss and neuropathy.
    • Improvement and stabilization of her blood glucose, evidenced by her most recent A1c of 6.9%, will significantly reduce risk for further catastrophic events and disease progression.

If you’re ready to lead, we’re ready to build.

The healthcare system won’t fix itself. But you don’t have to wait for reform.
You can design your own solution, and we can help you do it right.